PhaseBio
John Lee is currently the Chief Medical Officer at PhaseBio Pharmaceuticals, Inc. where John is responsible for prioritizing and accelerating the development of drug candidates. Prior to their current role, John held positions at Quintiles, Bristol-Myers Squibb, Merck, and the University of Pennsylvania, acquiring extensive experience in cardiovascular medicine and drug development. John's educational background includes a MD, PhD in Medicine and Biochemistry, and a BA in Biological Sciences from Harvard University.
This person is not in any offices
PhaseBio
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases.